公开(公告)号：US12162895B2

公开(公告)日：2024-12-10

申请号：US18600365

申请日：2024-03-08

Applicant: Breakpoint Therapeutics GmbH

Inventor： Andrea Guerrero Corella ,  Stuart Robert Flanagan ,  Jonathan Hollick ,  Julien Gilbert Jacques Malassis ,  Matthew Raymond Smith ,  Ian Andrew Yule ,  Jonathan Mark Bentley

IPC: C07D513/04 ,  A61K31/519

Abstract: The present invention relates to a compound of the Formula: or a pharmaceutically acceptable salt thereof. The compound of the present invention inhibits Polθ. This novel therapeutic compound is therefore useful for the treatment and/or prevention of diseases and conditions in which Polθ activity is implicated, such as, for example but not limited to, the treatment and/or prevention of cancer. The present invention also relates to pharmaceutical compositions comprising the novel therapeutic compound defined herein, to processes for synthesising the compound and to their use for the treatment of diseases and/or conditions in which Polθ activity is implicated.

公开(公告)号：US20240327430A1

公开(公告)日：2024-10-03

申请号：US18600352

申请日：2024-03-08

Applicant: Breakpoint Therapeutics GmbH

Inventor： Andrea Guerrero Corella ,  Stuart Robert Flanagan ,  Jonathan Hollick ,  Julien Gilbert Jacques Malassis ,  Matthew Raymond Smith ,  Ian Andrew Yule ,  Jonathan Mark Bentley

IPC: C07D513/04 ,  A61K31/4545

CPC classification number: C07D513/04 ,  A61K31/4545

Abstract: The present invention relates to a compound of the Formula:




or a pharmaceutically acceptable salt thereof.
The compound of the present invention inhibits Polθ. This novel therapeutic compound is therefore useful for the treatment and/or prevention of diseases and conditions in which Polθ activity is implicated, such as, for example but not limited to, the treatment and/or prevention of cancer. The present invention also relates to pharmaceutical compositions comprising the novel therapeutic compound defined herein, to processes for synthesising the compound and to their use for the treatment of diseases and/or conditions in which Polθ activity is implicated.

公开(公告)号：US12145945B2

公开(公告)日：2024-11-19

申请号：US18600352

申请日：2024-03-08

Applicant: Breakpoint Therapeutics GmbH

Inventor： Andrea Guerrero Corella ,  Stuart Robert Flanagan ,  Jonathan Hollick ,  Julien Gilbert Jacques Malassis ,  Matthew Raymond Smith ,  Ian Andrew Yule ,  Jonathan Mark Bentley

IPC: C07D513/04 ,  A61K31/4545

Abstract: The present invention relates to a compound of the Formula: and pharmaceutically salts thereof. The compound of the present invention inhibits Polθ. This novel therapeutic compound is therefore useful for the treatment and/or prevention of diseases and conditions in which Polθ activity is implicated, such as, for example but not limited to, the treatment and/or prevention of cancer. The present invention also relates to pharmaceutical compositions comprising the novel therapeutic compound defined herein, to processes for synthesising the compound and to their use for the treatment of diseases and/or conditions in which Polθ activity is implicated.

公开(公告)号：US20240336628A1

公开(公告)日：2024-10-10

申请号：US18600347

申请日：2024-03-08

Applicant: Breakpoint Therapeutics GmbH

Inventor： Andrea Guerrero Corella ,  Stuart Robert Flanagan ,  Jonathan Hollick ,  Julien Gilbert Jacques Malassis ,  Matthew Raymond Smith ,  Ian Andrew Yule ,  Jonathan Mark Bentley

IPC: C07D513/04 ,  A61K31/519

CPC classification number: C07D513/04 ,  A61K31/519

Abstract: The present invention relates to a compound of the Formula:




or a pharmaceutically acceptable salt thereof.
The compound of the present invention inhibits Polθ. This novel therapeutic compound is therefore useful for the treatment and/or prevention of diseases and conditions in which Polθ activity is implicated, such as, for example but not limited to, the treatment and/or prevention of cancer. The present invention also relates to pharmaceutical compositions comprising the novel therapeutic compound defined herein, to processes for synthesising the compound and to their use for the treatment of diseases and/or conditions in which Polθ activity is implicated.

公开(公告)号：US20240327431A1

公开(公告)日：2024-10-03

申请号：US18600365

申请日：2024-03-08

Applicant: Breakpoint Therapeutics GmbH

Inventor： Andrea Guerrero Corella ,  Stuart Robert Flanagan ,  Jonathan Hollick ,  Julien Gilbert Jacques Malassis ,  Matthew Raymond Smith ,  Ian Andrew Yule ,  Jonathan Mark Bentley

IPC: C07D513/04 ,  A61K31/519

CPC classification number: C07D513/04 ,  A61K31/519

Abstract: The present invention relates to a compound of the Formula:




or a pharmaceutically acceptable salt thereof.
The compound of the present invention inhibits Polθ. This novel therapeutic compound is therefore useful for the treatment and/or prevention of diseases and conditions in which Polθ activity is implicated, such as, for example but not limited to, the treatment and/or prevention of cancer. The present invention also relates to pharmaceutical compositions comprising the novel therapeutic compound defined herein, to processes for synthesising the compound and to their use for the treatment of diseases and/or conditions in which Polθ activity is implicated.